Clear Creek Financial Management’s Seres Therapeutics MCRB Stock Holding History

Clear Creek Financial Management’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-648	Closed	-$10.8K	–	538
2024 Q4	$10.8K	Sell	648 -262	-29%	-$4.26K	﹤0.01%	468
2024 Q3	$17.2K	Sell	910 -50	-5%	-$1.01K	﹤0.01%	456
2024 Q2	$13.9K	Sell	960 -213	-18%	-$3.55K	﹤0.01%	444
2024 Q1	$18.2K	Sell	1,173 -175	-13%	-$3.77K	﹤0.01%	419
2023 Q4	$37.7K	Sell	1,348 -1,225	-48%	-$32.2K	0.01%	340
2023 Q3	$122K	Sell	2,573 -137	-5%	-$10.5K	0.02%	312
2023 Q2	$260K	Buy	+2,710	New	+$295K	0.05%	269

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Clear Creek Financial Management's MCRB Position: Q1 2025 in Review

Clear Creek Financial Management sold out of Seres Therapeutics (MCRB) in Q1 2025, closing a stake of 648 shares — an estimated $10.8K sold.

Clear Creek Financial Management first reported a position in MCRB in Q2 2023 and held it in 7 quarters. The position peaked at $260K in Q2 2023. 63 funds tracked by Wall St. Rank hold MCRB as of Q1 2025.

Clear Creek Financial Management reported no remaining Seres Therapeutics position as of Q1 2025 after selling out during the quarter.
Clear Creek Financial Management sold 648 Seres Therapeutics shares in Q1 2025, an estimated $10.8K.
Clear Creek Financial Management first reported a position in Seres Therapeutics in Q2 2023 and held it in 7 quarters.
Clear Creek Financial Management's Seres Therapeutics position peaked at $260K in Q2 2023.
63 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2025.

Based on Clear Creek Financial Management's 13F filing for Q1 2025, filed 28 Apr 2025.